



STATE OF MARYLAND

DHMH

Maryland Department of Health and Mental Hygiene

Martin O'Malley, Governor – Anthony G. Brown, Lt. Governor – Joshua M. Sharfstein M.D., Secretary

Prevention and Health Promotion Administration

Michelle Spencer, MS, Director
Donna Gugel, MHS, Deputy Director

Ilise D. Marrazzo, RN, BSN, MPH, Director, Maternal and Child Health Bureau
Deborah B. McGruder, MPH, PMP, Director, Infectious Disease Bureau
Clifford S. Mitchell, MS, MD, MPH, Director, Environmental Health Bureau
Donald Shell, MD, MA, Director, Cancer and Chronic Disease Bureau

February 25, 2014

**Maryland Breast & Cervical
Cancer Program Medical
Advisory Committee**

Breast Cancer Subcommittee

Stanley P. Watkins, M.D.
Chairman
Annapolis Medical Specialists
Medical Oncology

Cecilia Brennecke, M.D.
Johns Hopkins Imaging
Breast Imaging Specialist

Robert Brookland, M.D.
Greater Baltimore Medical Center
Radiation Oncology/Therapy

Regina Hampton, M.D.
Doctor's Community Hospital
Breast Surgery

Kathy J. Helzlsouer, M.D.
Director
The Prevention and Research
Center
Weinberg Center for Women's
Health & Medicine
Mercy Medical Center

Nagi Khouri, M.D.
Johns Hopkins Medical Institutes
Radiation/Radiation Oncology

Lorraine Tafra, M.D.
Anne Arundel Medical Center
Breast Surgery

Dear Maryland Breast and Cervical Cancer Program Provider:

Thank you for providing breast cancer screening for uninsured or underinsured women aged 40-64 enrolled in the Maryland Breast and Cervical Cancer Program (BCCP). The Maryland BCCP is a grantee of the National Breast and Cervical Cancer Early Detection Program, funded by the Centers for Disease Control and Prevention (CDC). The policies of the national program are based on evidence in scientific literature and recommendations from national organizations such as the American Cancer Society, the United States Preventive Task Force, the National Comprehensive Cancer Network and the American College of Radiology.

We are pleased to enclose the **revised “Minimal Clinical Elements for Breast Cancer Detection and Diagnosis”** developed by the Medical Advisory Committee for the BCCP to serve as guidelines for the screening and management of women receiving breast cancer screening through the BCCP and diagnostic services through the BCCP Expanded.

The changes include:

- Clarification of mammogram type for women with a history of breast cancer.
- Guidelines for reimbursement for immunohistochemistry (IHC) for benign breast biopsy and reimbursement rate.
- Revisions to follow-up options after any CBE result with a mammogram result = BI-RADS 4 and negative biopsy.
- Clarification of reimbursement for surgical consult or follow-up visits.

201 W. Preston Street, Baltimore, Maryland 21201
410-767-6742 Fax 410-333-5995
Toll Free 1-877-4MD-DHMH TTY for Disabled
Maryland Relay Service 1-800-735-2258

500 N. Calvert Street, 5th Fl, Baltimore, Maryland 21202
410-767-5227 • Fax 410-333-6333 • TDD for Disabled 410-333-4800
Toll Free 1-800-358-9001 • TTY for Disabled
Maryland Relay Service 1-800-735-2258

Web Site: <http://phpa.dhmh.maryland.gov>

We appreciate your cooperation in using these new guidelines. If you have any questions regarding the new “Minimal Clinical Elements for Breast Cancer Detection and Diagnosis” for the Maryland Breast and Cervical Cancer Program, please contact Courtney Lewis, Director of the Center for Cancer Prevention and Control (CCPC) at (410) 767- 0824 or Courtney.lewis@maryland.gov.

Sincerely,



Stanley Watkins, M.D.

Chairman, Medical Advisory Committee

Maryland Breast and Cervical Cancer Program

Enclosure

Cc Courtney Lewis, M.P.H., Director, CCPC
Dawn Henninger, R.N., M.S., Program Manager, BCCP
Holly Harshbarger, R.N., B.S., Program Nurse Consultant, BCCP
Local BCCP Coordinators

Minimal Clinical Elements for Breast Cancer Detection and Diagnosis
Maryland Breast and Cervical Cancer Program
Maryland DHMH, Center for Cancer Prevention and Control
January 2014

Goal:

The goal of the Minimal Clinical Elements for Breast Cancer Detection and Diagnosis is to provide clients of the Maryland Breast and Cervical Cancer Program (BCCP) with optimal, up-to-date screening for breast cancer and management of findings

Objective:

- To provide clinical guidelines for breast cancer screening and diagnostic testing including interpretation and management of results of clinical breast examination, mammography, and diagnostic testing.
- To outline appropriate management and approved indications for procedure payment.

Detection and Management of Breast Abnormalities in the Breast and Cervical Cancer Program—Breast Cancer Minimal Clinical Elements

Section	Page
I. Maryland Breast and Cervical Cancer Program (BCCP)— Eligibility for Screening, Procedures for Screening or Initial Testing, and Eligibility for Expanded Diagnostic Testing	
A. BCCP Eligibility and Procedures for Screening or Initial Testing	3
B. Eligibility for Diagnostic Testing in the BCCP Expanded Services	4
II. Findings, Management of Results, Additional Procedures and Program Coverage	
A. Results and Reports	5
B. Management of Findings of CBE, Initial Mammogram, and Testing	6
C. Additional Procedures and Program Coverage	6
Attachment A	8
Flow Charts of the Maryland Breast and Cervical Cancer Program: Management of Clinical Breast Examination and Mammogram Results	
I. Management when the Clinical Breast Exam is <i>Normal/Benign</i>	9
II. Management when the Clinical Breast Exam is <i>Abnormal</i>	10

**Members of the Breast Cancer Subcommittee of the
BCCP Medical Advisory Committee:**

Stanley Watkins, M.D., Chairman
Hematologist/Oncologist
Annapolis Medical Specialists
Assistant Professor of Oncology, The Johns Hopkins School of Medicine (part time)

Cecilia Brennecke, M.D.
Medical Director, Johns Hopkins Imaging
Diagnostic Radiology

Robert Brookland, M.D.
Radiation Oncology/Radiation Therapy
Greater Baltimore Medical Center

Regina Hampton, M.D. FACS
Medical Director, Center for Women's Wellness
Doctor's Community Hospital

Kathy J. Helzlsouer, M.D., M.H.S.
Director, The Prevention and Research Center
The Weinberg Center for Women's Health and Medicine
Mercy Medical Center

Nagi Khouri, M.D.
Associate Professor of Radiology and Radiological Science
Associate Professor of Oncology
Johns Hopkins Medical Institutions

Lorraine Tafra, M.D.
Breast Surgery
Anne Arundel Medical Center

Staff for the Breast Cancer Subcommittee
Center for Cancer Prevention and Control, Maryland Dept. of Health and Mental Hygiene
Courtney Lewis, M.P.H., Director, CCPC
Diane Dwyer, M.D., Medical Director, CCPC
Dawn Henninger, R.N., M.S., Program Manager, BCCP
Holly Harshbarger, R.N., B.S. Program Nurse Consultant, BCCP

Detection and Management of Breast Abnormalities in the Breast and Cervical Cancer Program

Breast Cancer Minimal Clinical Elements (MCE)

I. Maryland Breast and Cervical Cancer Program (BCCP)—Eligibility for Screening, Procedures for Screening or Initial Testing, and Eligibility for Expanded Diagnostic Testing

A. BCCP Eligibility and Procedures for Screening or Initial Testing

1. A woman is eligible for breast cancer screening with clinical breast examination (CBE) and mammogram in the BCCP *regardless* of symptoms, risk factors, or prior breast cancer/findings if she:
 - a. Is 40 – 64 years old or 65+ without Medicare Part B;
 - b. Meets income eligibility of household income <250% of the Federal Poverty Guideline;
 - c. Has no health insurance, has health insurance that does not cover breast cancer screening, or has coverage but has not met deductible for the year; **and**
 - d. Has **not** had bilateral mastectomies.

2. A woman should have a **diagnostic mammogram** if a woman has:
 - a. A CBE with results that include:
 - i. Nipple discharge that is:
 - (a) Bloody;
 - (b) Crystal clear (like water); or
 - (c) Any other color or clarity (for example, yellow, white, milky, gray, green) if the discharge is unilateral, single duct, and spontaneous.
 - ii. Discrete palpable mass—suspicious for cancer;
 - iii. Nipple/areolar scaliness; or
 - iv. Skin dimpling/retraction;
 - b. A recommendation for a diagnostic mammogram from the Medical Case Manager.

3. A woman should have a **screening mammogram** as the annual exam if the woman has:
 - a. A CBE with Normal findings or a CBE with Benign findings, including:
 - i. Nipple discharge that does not meet the requirement for diagnostic mammogram (2., a., i., above);
 - ii. Breast implant(s);
 - iii. Fibrocystic changes,
 - iv. Mastitis;
 - v. “Lumpy” breasts;
 - vi. Family history of breast cancer (premenopausal breast cancer in sister/mother);or

- vii. Prior benign biopsy (within past year) when surgeon or radiologist recommends screening mammogram.
 - b. A history of negative screening mammogram(s) (American College of Radiology, Breast Imaging and Database Reporting System [BI-RADS] category 1, negative, or BI-RADS 2, benign finding).
- 4. A woman with a prior history of breast cancer (in situ or invasive, in patient who has not had bilateral mastectomies) should have a:
 - a. Diagnostic mammogram for 5 years post diagnosis then;
 - b. May resume screening mammogram after 5 years at the discretion of the medical case manager, radiologist and client.
- 5. CBE should be performed 90 days prior to the screening mammogram.
 - a. Each breast should be examined including the retroareolar and peripheral areas and the upper lateral quadrant into the axilla.
 - b. The preferred method of CBE is the strip technique using three levels of pressure in small circular motions with pad of three middle fingers without lubrication (MammaCare® method).

B. Eligibility for Diagnostic Testing in the BCCP Expanded Services

A woman is eligible for breast cancer diagnostic testing **in the BCCP Expanded Services** if she:

1. Is 40 – 64 years old, or 65+ without Medicare Part B;
2. Meets income eligibility of <250% of the Federal Poverty Guideline;
3. Has no health insurance, has health insurance that does not cover breast cancer diagnostic testing/visits, or has coverage but has not met deductible for the year;
4. Has not had bilateral mastectomies; and
5. Provides the BCCP with a recommendation from a clinician for diagnostic workup and test results of:
 - a. CBE requiring further diagnosis (see I. A. 2. a.);
 - b. Mammogram requiring further diagnosis;
 - c. Ultrasound abnormal finding other than simple cyst(s); or
 - d. Persistent, unexplained, localized pain in the breast with a negative mammogram.

II. Findings, Management of Results, Additional Procedures, and Program Coverage

A. Results and Reports

1. CBE findings:

a. Should be reported as:

i. Normal exam

ii. Benign findings

iii. Abnormal findings:

1. Nipple discharge that is bloody, crystal clear (like water) or any other color or clarity (for example, yellow, white, milky, gray, green) if the discharge is unilateral, single duct, and spontaneous.

2. Discrete palpable mass—suspicious for cancer

3. Nipple/areolar scaliness

4. Skin dimpling/retraction

b. CBE should report whether there are breast implants; however, this finding would be categorized as a “Benign finding” if no other abnormalities were found.

c. CBE should report whether the patient has had a lumpectomy or a mastectomy and which breast was affected; however, this finding would be categorized as a “Benign finding” if no other abnormalities were found.

2. Mammogram findings should be reported using American College of Radiology BI-RADS® (Breast Imaging-Reporting and Database System) Assessment Categories:

a. Assessment is Incomplete

0 Need Additional Imaging Evaluation and/or Prior Mammograms for Comparison

b. Assessment is Complete – Final Categories

1 Negative

2 Benign Finding(s)

3 Probably Benign Finding – Initial Short-Interval Follow-Up Suggested

4 Suspicious Abnormality – Biopsy Should Be Considered

5 Highly Suggestive of Malignancy – Appropriate Action Should Be Taken

6 Known Biopsy-Proven Malignancy – Appropriate Action Should Be Taken

(Category reserved for lesions identified on imaging study with biopsy proof of malignancy prior to definitive therapy)

Ref. The American College of Radiology BI-RADS® ATLAS and MQSA: Frequently Asked Questions (Updated: 7/1/09)

c. **Breast composition on mammogram** should be described for all patients using the following patterns:

i. The breast is almost entirely fat (<25% glandular)

ii. There are scattered fibroglandular densities (approximately 25-50% glandular)

iii. The breast tissue is heterogeneously dense, which could obscure detection of small masses (approximately 51-75% glandular)

- iv. The breast tissue is extremely dense. This may lower the sensitivity of mammography (>75% glandular).

Ref. 2003 ACR® BI-RADS Atlas

3. **Ultrasound definitions:** The terms “simple cyst,” “complicated cyst,” and “complex cyst” are defined by the radiologist and stated in the report of an ultrasound examination.
4. The radiologist’s diagnostic workup/evaluation report should include the results of the diagnostic mammogram, ultrasound (when performed), CBE, and the correlation of each test with each other.

B. Management of Findings of CBE, Initial Mammogram, and Testing

1. **See Attachment A.** Flow Charts of the Maryland Breast and Cervical Cancer Program: Management of Clinical Breast Examination and Mammogram Results.
2. A woman with persistent, unexplained, localized pain in the breast should be evaluated by a breast specialist or surgeon.
3. If a radiologist recommends obtaining results or copies of prior mammograms following a BI-RADS category 0 result, local programs should assist in obtaining the results or copies.
4. Image-guided percutaneous needle biopsy is the diagnostic procedure of choice for image-detected abnormalities, with few exceptions.
5. When a non-palpable or questionably palpable mass that was found on imaging is excised, the specimen should be verified by using the appropriate imaging modality while the patient is still in the operating room.
6. At least one breast tissue specimen positive for cancer should be tested for tumor markers (e.g. estrogen/progesterone receptors, her2neu etc.) to guide clinical management.

C. Additional Procedures and Program Coverage

1. Providers should consult with the local BCCP for questions about coverage for payment of procedures.
2. Magnetic Resonance Imaging (MRI)
 - a. The DHMH BCCP **will not reimburse** for MRI for breast cancer **screening**.
 - b. If recommended by the managing physician, the BCCP **will reimburse** for a MRI of the breast for:
 - i. Extent of disease in the ipsilateral breast in patients with a recent diagnosis of breast cancer;

- ii. Screening of the contralateral breast in women with a current, newly diagnosed, unilateral breast cancer;
 - iii. Evaluation of patients undergoing current neoadjuvant chemotherapy for breast cancer;
 - iv. Positive margins after surgery for breast malignancy; or
 - v. Chest wall invasion suspected.
- c. The BCCP **will not reimburse** for MRI of the breast for:
- i. Surveillance of breast findings (for example, the program will not reimburse for MRI follow-up every 3-6 months for a surgical consult of “benign findings”);
 - ii. Problem solving for inconclusive clinical or mammographic findings; or
 - iii. Evaluation of silicone breast implant integrity.
3. The BCCP will reimburse for a surgical or breast specialist consultation for a woman who has a negative mammogram but who has persistent, unexplained, localized pain in the breast.
4. BCCP funds surgical consults or follow-up visits intended to confirm or rule out breast cancer when screening tests yield abnormal results. BCCP will:
- a. Reimburse a maximum of two consults or visits to the same breast surgeon for the same breast problem (initial consultation plus a follow-up consultation).
 - b. Reimburse follow-up of post-operative/post-biopsy complications of infection, hematoma, etc., following a BCCP-funded biopsy.
 - c. Consider reimbursement on a case-by-case basis for follow-up surgical visits where the surgical pathology may be associated with recurrence or the presence of a more severe abnormality in the breast (e.g. certain types of atypia, phyllodes tumors) and the surgeon recommends short-term follow-up (every 3-6 months) for a maximum of 12 months.
 - d. Not reimburse for on-going surveillance for those cases in which the medical case manager or surgeon recommends frequent follow-up visits for surveillance based on a benign breast condition that is considered chronic and or based on a woman’s risk factors.
5. The BCCP will reimburse for immunohistochemical (IHC) stains as indicated below:
- a. When cancer is diagnosed on the biopsy: the BCCP will reimburse for IHC stains ordered by the clinician or pathologist.
 - b. When cancer is suspected or needs to be ruled out: IHC should not be used reflexively to evaluate every breast biopsy. IHC is best used when ordered by the pathologist where IHC will clarify an ambiguous pathologic diagnosis. The most frequent use of this is where the pathologist wants to know whether an adenoma or papilloma harbors invasive disease, or whether the tumor is ductal or lobular. The BCCP will reimburse in these cases but may request more information to justify the use of IHC.

This page intentionally left blank

Attachment A


Flow Charts of the Maryland Breast and Cervical Cancer Program:

Management of Clinical Breast Examination and Mammogram Results

- I. Management when Clinical Breast Examination is Normal/Benign Findings**

- II. Management when Clinical Breast Examination is Abnormal**

Management of Clinical Breast Exam and Mammogram Results:



*Please refer to The Minimal Clinical Elements for Breast Cancer Detection and Diagnosis, Section II, C, number 4 page 7 for further details and program coverage.


DCIS: Ductal carcinoma in situ
LCIS: Lobular carcinoma in situ

Management of Clinical Breast Exam and Mammogram Results:

Clinical Breast Examination: Abnormal (other than Normal or Benign Finding) **

Diagnostic mammogram (always); with Ultrasound, if recommended

CBE, Mammogram, and Ultrasound Results



* Please refer to The Minimal Clinical Elements for Breast Cancer Detection and Diagnosis, Section II, C, number 4 page 7 for further details and program coverage.

DCIS: Ductal carcinoma in situ
LCIS: Lobular carcinoma in situ

** "Abnormal Clinical Breast Exam" includes:
-Nipple discharge that is bloody, crystal clear, or of any color if unilateral, single duct, and spontaneous;
-Discrete palpable mass—suspicious for cancer
-Nipple/areolar scaliness
-Skin dimpling/retraction